Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells

Tyrosine kinase inhibitor (TKI) treatment has dramatically improved the survival of chronic myeloid leukemia (CML) patients, but measurable residual disease typically persists. To more effectively eradicate leukemia cells, simultaneous targeting of BCR-ABL1 and additional CML-related survival protei...

Descripción completa

Detalles Bibliográficos
Autores principales: Malyukova, Alena, Ujvari, Dorina, Yektaei-Karin, Elham, Zovko, Ana, Madapura, Harsha S., Keszei, Marton, Nagy, Noemi, Lotfi, Kourosh, Björn, Niclas, Wallvik, Jonas, Tamai, Minori, Nguyen, Thao T. T., Akahane, Koshi, Inukai, Takeshi, Stenke, Leif, Salamon, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464601/
https://www.ncbi.nlm.nih.gov/pubmed/34564697
http://dx.doi.org/10.1038/s41419-021-04154-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464601/
https://www.ncbi.nlm.nih.gov/pubmed/34564697
http://dx.doi.org/10.1038/s41419-021-04154-0

Ejemplares similares